The haemodynamic response is rapid delivery of blood to active neuronal tissue. Complications in this response arise in acute coronary syndromes and
pulmonary arterial hypertension. These complications lead to a change in the regulation of blood flow to the brain, and in turn the amount of glucose and oxygen that is supplied to neurons, which may have serious effects not only on the functioning of the nervous system, but functioning of all bodily systems.
Acute coronary syndrome Acute infections, such as
community-acquired pneumonia (CAP), act as a trigger for
acute coronary syndromes (ACS). ACS deals with symptoms that result from the obstruction of coronary
arteries. Due to this obstruction there are
thrombotic complications at the sites of
atherosclerotic plaques. The most common symptom that prompts diagnosis is chest pain, associated with nausea and sweating. Treatment usually includes
aspirin,
Clopidogrel,
nitroglycerin, and if chest pain persists
morphine. Recent study suggests that acute respiratory tract infection can act as a trigger for ACS. This in turn has major prothrombotic and haemodynamic effects. Overall, pulmonary arterial tension and acute coronary syndromes are few of the many diseases that lead to hypoxia of neuronal tissue, which in turns deteriorates the haemodynamic response and leads to neuronal death. Prolonged hypoxia induces neuronal death via apoptosis. With a dysfunctional haemodynamic response, active neuronal tissue due to membrane depolarization lacks the necessary energy to propagate signals, as a result of blood flow hindrance. This affects many functions in the body, and may lead to severe symptoms.
Reduced haemodynamic response diseases Alzheimer's disease In this disease, there is a build of the
amyloid beta protein in the brain. This ultimately leads to a reduction in the haemodynamic response and less blood flow in the brain. This reduced cerebral blood flow not only kills neuronal cells because of shortages in oxygen and glucose but it also reduces the brain's ability to remove amyloid beta. In a healthy brain, these protein fragments are broken down and eliminated. In Alzheimer's disease, the fragments accumulate to form hard, insoluble plaques which reduce blood flow. Two proteins are involved in this accumulation of amyloid beta:
serum response factor or
SRF and myocardin. Together, these 2 proteins determine whether smooth muscle of blood vessels contract. SRF and myocardin are more active in the brains of people with Alzheimer's disease. When these proteins are active, they turn on SREBP2 which inhibits LRP-1. LRP-1 helps the brain remove amyloid beta. Therefore, when SRF and myocardin are active, there is a buildup in amyloid beta protein which ultimately leads to less blood flow in the brain because of contracted blood vessels.
Ischemia A decrease in circulation in the brain vasculature due to
stroke or injury can lead to a condition known as
ischemia. In general, decrease in blood flow to the brain can be a result of thrombosis causing a partial or full blockage of blood vessels,
hypotension in systemic circulation (and consequently the brain), or cardiac arrest. This decrease in blood flow in the cerebral vascular system can result in a buildup of metabolic wastes generated by neurons and glial cells and a decrease in oxygen and glucose delivery to them. As a result, cellular energy failure, depolarization of neuronal and glial membranes,
edema, and excess
neurotransmitter and calcium ion release can occur. This ultimately ends with cell death, as cells succumb to a lack of nutrients to power their metabolism and to a toxic brain environment, full of free radicals and excess ions that damage normal cell organelle function. ==Clinical use==